PPARA and metabolic dysfunction-associated steatotic liver disease: Pharmacological agents targeting lipid metabolism pathways, such as PPAR agonists and SREBP inhibitors, have shown potential in preclinical studies, but no specific drug has been approved for NAFLD treatment due to concerns over safety, efficacy, and prolonged administration [13,14,15].